IL139452A0 - Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of diseases associated with angiogenesis - Google Patents
Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of diseases associated with angiogenesisInfo
- Publication number
- IL139452A0 IL139452A0 IL13945299A IL13945299A IL139452A0 IL 139452 A0 IL139452 A0 IL 139452A0 IL 13945299 A IL13945299 A IL 13945299A IL 13945299 A IL13945299 A IL 13945299A IL 139452 A0 IL139452 A0 IL 139452A0
- Authority
- IL
- Israel
- Prior art keywords
- angiogenesis
- scintigraphy
- treatment
- antibodies
- specific binding
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000009870 specific binding Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 210000004204 blood vessel Anatomy 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000003504 photosensitizing agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7533898A | 1998-05-11 | 1998-05-11 | |
| US09/300,425 US20030045681A1 (en) | 1998-05-11 | 1999-04-28 | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| PCT/EP1999/003210 WO1999058570A2 (en) | 1998-05-11 | 1999-05-11 | Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL139452A0 true IL139452A0 (en) | 2001-11-25 |
Family
ID=26756726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13945299A IL139452A0 (en) | 1998-05-11 | 1999-05-11 | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of diseases associated with angiogenesis |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20070189963A1 (xx) |
| EP (1) | EP1084145B1 (xx) |
| JP (1) | JP2002514405A (xx) |
| CN (1) | CN1250571C (xx) |
| AT (1) | ATE301676T1 (xx) |
| AU (1) | AU759207B2 (xx) |
| BR (1) | BRPI9910394B8 (xx) |
| CA (1) | CA2333833C (xx) |
| CZ (1) | CZ300495B6 (xx) |
| DE (1) | DE69926630T2 (xx) |
| DK (1) | DK1084145T3 (xx) |
| EA (1) | EA005685B1 (xx) |
| EE (1) | EE05435B1 (xx) |
| ES (1) | ES2247802T3 (xx) |
| HU (1) | HU225675B1 (xx) |
| IL (1) | IL139452A0 (xx) |
| IS (1) | IS2522B (xx) |
| NO (1) | NO327732B1 (xx) |
| NZ (1) | NZ508600A (xx) |
| PL (1) | PL199353B1 (xx) |
| SK (1) | SK286822B6 (xx) |
| TR (1) | TR200003317T2 (xx) |
| TW (1) | TWI259837B (xx) |
| WO (1) | WO1999058570A2 (xx) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| DE69932084T2 (de) * | 1999-01-05 | 2007-06-28 | The Flinders University Of South Australia, Bedford Park | Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| DE19947559A1 (de) * | 1999-09-24 | 2001-04-19 | Schering Ag | Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung |
| US6319273B1 (en) * | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
| AU4243201A (en) * | 2000-02-24 | 2001-09-03 | Eidgenoess Tech Hochschule | Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis |
| ES2373966T3 (es) * | 2000-02-24 | 2012-02-10 | Philogen S.P.A. | Composiciones y procedimientos para el tratamiento de la angiogénesis en lesiones patológicas. |
| DE10045803A1 (de) * | 2000-09-07 | 2002-04-11 | Schering Ag | Rezeptor der EDb Fibronektin-Domäne |
| US20020197700A1 (en) * | 2000-09-07 | 2002-12-26 | Schering Ag | Receptor of the EDb-fibronectin domains |
| US20030100010A1 (en) * | 2001-11-23 | 2003-05-29 | George Jackowski | Fibrinogen biopolymer Marker predictive of type II diabetes |
| EP1453546A2 (en) * | 2001-12-04 | 2004-09-08 | Nanospectra Biosciences, Inc. | Treatment of angiogenesis disorders using targeted nanoparticles |
| BR0306715A (pt) * | 2002-01-03 | 2004-12-28 | Schering Ag | Métodos para diagnóstico e tratamento de tumores |
| PT1461360E (pt) * | 2002-01-03 | 2010-11-23 | Bayer Schering Pharma Ag | Conjugados compreendendo um anticorpo específico para o domínio ed-b de fibronectina e suas utilizações para a detecção e tratamento de tumores |
| WO2003076469A2 (en) * | 2002-03-11 | 2003-09-18 | Philogen S.P.A. | Antibodies derived rom anti ed-b l19 and targeting tumor vasculature |
| DK2269656T3 (da) | 2002-07-15 | 2014-11-03 | Univ Texas | Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| DE10348319A1 (de) * | 2003-10-17 | 2005-05-19 | Schering Ag | Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| WO2007056441A2 (en) * | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| DE502005009389D1 (de) * | 2005-11-09 | 2010-05-20 | Morphosys Ag | Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern |
| EP1842553A1 (en) | 2006-04-07 | 2007-10-10 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
| EP1925664A1 (en) | 2006-11-15 | 2008-05-28 | Scil proteins GmbH | Artificial binding proteins based on a modified alpha helical region of ubiquitin |
| ATE548052T1 (de) | 2008-01-17 | 2012-03-15 | Philogen Spa | Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler |
| EP2100621A1 (en) | 2008-03-10 | 2009-09-16 | mivenion GmbH | Polyether polyol dendron conjugates with effector molecules for biological targeting |
| JP2009244154A (ja) | 2008-03-31 | 2009-10-22 | Nationa Hospital Organization | 老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法 |
| EP2116555A1 (en) | 2008-05-08 | 2009-11-11 | Bayer Schering Pharma Aktiengesellschaft | Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma |
| US20110306065A1 (en) * | 2008-11-12 | 2011-12-15 | The Trustees Of The University Of Pennsylvania | Use of an antibody and a rare-earth based crystal |
| AU2010332938B2 (en) | 2009-12-14 | 2012-12-20 | Navigo Proteins Gmbh | A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
| WO2011110490A1 (en) | 2010-03-09 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | Process for the production of radioactively labelled scfv antibody fragments, kits and compositions |
| EP2721152B1 (en) | 2011-06-15 | 2019-03-27 | Navigo Proteins GmbH | Dimeric binding proteins based on modified ubiquitins |
| WO2012171541A1 (en) | 2011-06-15 | 2012-12-20 | Scil Proteins Gmbh | Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins |
| US9549981B2 (en) | 2011-07-19 | 2017-01-24 | Philogen S.P.A. | Sequential antibody therapy |
| RU2481839C2 (ru) * | 2011-08-16 | 2013-05-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет Министерства здравоохранения и социального развития" | Способ лечения ишемической болезни сердца с дистальным или диффузным поражением коронарных артерий |
| US20150183846A1 (en) | 2012-06-13 | 2015-07-02 | Scil Proteins Gmbh | Human fusion proteins comprising single chain tnfalpha and targeting domains |
| WO2014094799A1 (en) | 2012-12-19 | 2014-06-26 | Scil-Proteins-Gmbh | Ubiquitin moieties as a means for prolonging serum half-life |
| EP3029065B1 (en) * | 2013-06-06 | 2020-05-27 | Hefei Lifeon Pharmaceutical Co. Ltd. | Human antibody against ed-b domain of fibronectin and uses thereof |
| CA2975362A1 (en) | 2015-02-06 | 2016-08-11 | Navigo Proteins Gmbh | Egfr binding proteins comprising ubiquitin muteins |
| BR112018000477A2 (pt) | 2015-07-16 | 2018-09-18 | Navigo Proteins Gmbh | proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural |
| US10584152B2 (en) | 2015-07-20 | 2020-03-10 | Navigo Proteins Gmbh | Binding proteins based on di-ubiquitin muteins and methods for generation |
| US20180340936A1 (en) * | 2015-11-16 | 2018-11-29 | Hefei Lifeon Pharmaceutical Co. Ltd. | Use of ed-b protein in diagnosis of tissue hyperplasia |
| EP3452097A1 (en) | 2016-05-04 | 2019-03-13 | Navigo Proteins GmbH | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
| GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| CN117736281A (zh) | 2016-08-11 | 2024-03-22 | 瑞普利金公司 | 用于亲和色谱的碱性稳定性fc结合蛋白 |
| EP3525828B1 (en) | 2016-10-17 | 2024-12-25 | Pfizer Inc. | Anti-edb antibodies and antibody-drug conjugates |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| CN117430699A (zh) | 2017-09-30 | 2024-01-23 | 合肥立方制药股份有限公司 | 结合至纤维连接蛋白b结构域的蛋白 |
| WO2019091918A1 (en) | 2017-11-07 | 2019-05-16 | Navigo Proteins Gmbh | Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| WO2020070150A1 (en) | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
| EP3660039A1 (en) | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2 immunoconjugates |
| BR112023027305A2 (pt) | 2021-06-23 | 2024-03-12 | Cytune Pharma | Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica |
| US20240294594A1 (en) | 2021-06-23 | 2024-09-05 | Cytune Pharma | Interleukin-15 based immunocytokines |
| EP4440599A1 (en) | 2022-01-04 | 2024-10-09 | Philogen S.p.A. | Combination of an immunocytokine comprising il-12 and a kinase inhibitor |
| WO2024028258A1 (en) | 2022-08-01 | 2024-02-08 | Philochem Ag | Conjugates of psma-binding moieties with cytotoxic agents |
| CN119836298A (zh) | 2022-09-01 | 2025-04-15 | 菲洛根股份公司 | 用于非黑色素瘤皮肤癌的TNFα和白细胞介素-2组合疗法 |
| JP2025529319A (ja) | 2022-09-06 | 2025-09-04 | フィロケム・アーゲー | 標的送達用途のための多価線維芽細胞活性化タンパク質リガンド |
| WO2025061801A1 (en) | 2023-09-19 | 2025-03-27 | Philochem Ag | Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9610967D0 (en) * | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
-
1999
- 1999-05-10 TW TW088107648A patent/TWI259837B/zh active
- 1999-05-11 EE EEP200000802A patent/EE05435B1/xx not_active IP Right Cessation
- 1999-05-11 CZ CZ20004216A patent/CZ300495B6/cs not_active IP Right Cessation
- 1999-05-11 EA EA200001169A patent/EA005685B1/ru not_active IP Right Cessation
- 1999-05-11 AT AT99923571T patent/ATE301676T1/de active
- 1999-05-11 JP JP2000548372A patent/JP2002514405A/ja active Pending
- 1999-05-11 BR BRPI9910394-0B1 patent/BRPI9910394B8/pt not_active IP Right Cessation
- 1999-05-11 WO PCT/EP1999/003210 patent/WO1999058570A2/en active IP Right Grant
- 1999-05-11 SK SK1679-2000A patent/SK286822B6/sk not_active IP Right Cessation
- 1999-05-11 EP EP99923571A patent/EP1084145B1/en not_active Expired - Lifetime
- 1999-05-11 IL IL13945299A patent/IL139452A0/xx unknown
- 1999-05-11 HU HU0102992A patent/HU225675B1/hu not_active IP Right Cessation
- 1999-05-11 TR TR2000/03317T patent/TR200003317T2/xx unknown
- 1999-05-11 AU AU40398/99A patent/AU759207B2/en not_active Expired
- 1999-05-11 NZ NZ508600A patent/NZ508600A/xx unknown
- 1999-05-11 CA CA2333833A patent/CA2333833C/en not_active Expired - Lifetime
- 1999-05-11 PL PL345845A patent/PL199353B1/pl not_active IP Right Cessation
- 1999-05-11 DK DK99923571T patent/DK1084145T3/da active
- 1999-05-11 CN CNB998060526A patent/CN1250571C/zh not_active Expired - Lifetime
- 1999-05-11 DE DE69926630T patent/DE69926630T2/de not_active Expired - Lifetime
- 1999-05-11 ES ES99923571T patent/ES2247802T3/es not_active Expired - Lifetime
-
2000
- 2000-11-10 IS IS5708A patent/IS2522B/is unknown
- 2000-11-10 NO NO20005694A patent/NO327732B1/no not_active IP Right Cessation
-
2006
- 2006-12-13 US US11/637,810 patent/US20070189963A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL139452A0 (en) | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of diseases associated with angiogenesis | |
| EP1590434A4 (en) | ASSOCIATED ANTIGEN, ANTIBODIES, AND DIAGNOSIS AND TREATMENT METHODS WITH CONCENTRATED CANNULA CANCER | |
| MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
| KR102414718B1 (ko) | 암의 진단 및 치료를 위한 조성물 및 방법 | |
| WO2002046222A3 (en) | Compositions and methods for diagnosing alzheimer's disease | |
| ES2061730T3 (es) | Nuevos anticuerpos. | |
| ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| DE69942802D1 (de) | Trifunktionales reagenz zur verbindung von biomolekülen | |
| UA89759C2 (ru) | Специфический связующий элемент, радиоактивно меченный 131и, который связывает человеческий ed-в фибронектина | |
| DE60014064D1 (de) | Einetenascin-c isoform als marker für neoplasmen | |
| BG105030A (en) | Antibodies against ed-b domain of fibronectin, conjugates containing them, and their application for diagnostics and treatment of tumours and morbid conditions related to angiogenesis | |
| JP7466466B2 (ja) | 癌の診断および治療のための組成物および方法 | |
| AU2002233278A1 (en) | Method and use of the cytosolic nadp-dependent malate-decarboxylase isoenzyme for identifying a malignant process, and a suitable test kit | |
| SI1084145T1 (sl) | Protitelesa za ED-B domeno fibronektina, konjugati, ki jih vsebujejo, in njihova uporaba za diagnozo in terapijo tumorjev in bolezni povezanih z angiogenezo | |
| BR9815776A (pt) | Anticorpos monoclonais anti-tag-72 humanizados com alta afinidade |